What side effects are associated with this type of intervention?

Common treatments for Small Cell Lung Cancer (SCLC) include chemotherapy, immunotherapy, and targeted therapies like Tarlatamab. Chemotherapy regimens, such as etoposide combined with either cisplatin or carboplatin, often cause side effects like nausea, vomiting, hair loss, fatigue, and increased risk of infections due to bone marrow suppression. Immunotherapy, including anti-PD-1 or anti-PD-L1 therapies, can lead to immune-related adverse effects such as colitis, pneumonitis, hepatitis, and endocrinopathies. Targeted therapies like Tarlatamab, which aim to enhance anti-tumor activity by targeting specific cancer cells, may also cause similar immune-related side effects, along with potential infusion-related reactions.

What prior FDA approvals exist?

FDA-approved treatments for Small Cell Lung Cancer (SCLC) that target specific cancer cells include immune checkpoint inhibitors such as nivolumab and pembrolizumab. These drugs work by targeting the PD-1/PD-L1 pathway, enhancing the immune system's ability to attack cancer cells. Additionally, atezolizumab, another immune checkpoint inhibitor, has been approved for use in combination with chemotherapy (etoposide and carboplatin/cisplatin) for extensive-stage SCLC. These treatments are similar to Tarlatamab, which is being studied for its anti-tumor activity by targeting specific cancer cells.

What other types of research exist?

Promising novel alternatives to Tarlatamab for SCLC patients include Larotrectinib, a highly selective TRK inhibitor effective in TRK fusion-positive cancers, and investigational approaches combining EGFR antibody targeting with T cell-mediated cytotoxicity. Additionally, novel EML4-ALK inhibitors and MEK inhibitors are in clinical development and may offer targeted therapeutic options.

← Back to Search

Monoclonal Antibodies

Tarlatamab for Small Cell Lung Cancer (DeLLphi-301 Trial)

Hanover, NH

Phase 2

Waitlist Available

Research Sponsored by Amgen

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Histologically or cytologically confirmed relapsed/refractory SCLC

Participants who progressed or recurred following 1 platinum-based regimen and at least 1 other prior line of therapy.

Must not have

Female participants of childbearing potential with a positive pregnancy test assessed at screening and/or day 1 by a highly sensitive urine or serum pregnancy test.

Untreated or symptomatic brain metastases and leptomeningeal disease.

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

No Placebo-Only Group

Summary

This trial is testing tarlatamab, a new medication aimed at treating solid tumors. It focuses on patients whose tumors may not respond well to other treatments. Tarlatamab works by helping the immune system recognize and destroy cancer cells.

See full description

Who is the study for?

This trial is for adults over 18 with relapsed/refractory Small Cell Lung Cancer (SCLC) who have tried at least one platinum-based therapy and another treatment. They must have a life expectancy of at least 12 weeks, measurable cancer lesions, and be in fairly good health (ECOG status of 0 or 1). Participants with treated brain metastases may join if they meet certain criteria. Pregnant women, those planning to become pregnant, or breastfeeding are excluded, as well as anyone unwilling to use contraception.Check my eligibility

What is being tested?

The study tests two dose levels of Tarlatamab for safety and effectiveness against SCLC tumors. It's divided into parts: the first evaluates safety/effectiveness per RECIST 1.1 standards; the second assesses tumor response rate by independent review; the third looks at safety regarding reduced monitoring after initial doses.See study design

What are the potential side effects?

While specific side effects aren't listed here, common ones from treatments like Tarlatamab can include immune-related reactions such as inflammation in organs, fatigue, infusion reactions similar to allergic responses during drug administration, digestive issues like nausea or diarrhea, blood disorders affecting cell counts leading to increased infection risk.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My small cell lung cancer has come back or didn't respond to treatment.

show original

Select...

My cancer returned or worsened after 1 platinum-based treatment and another therapy.

show original

Select...

I am fully active or restricted in physically strenuous activity but can do light work.

show original

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I am not pregnant, as confirmed by a sensitive test.

show original

Select...

I have brain metastases or leptomeningeal disease that hasn't been treated or is causing symptoms.

show original

Select...

I have a lung condition not caused by an infection.

show original

Select...

I had severe reactions to previous immune therapy.

show original

Select...

I have not had major surgery in the last 4 weeks.

show original

Select...

I have not taken steroids or immunosuppressants in the last 7 days.

show original

Select...

I haven't had signs of a serious infection in the last week.

show original

Select...

I have had issues with my pituitary gland.

show original

Select...

I am not breastfeeding nor plan to while on the study and for 72 days after the last dose.

show original

Select...

I have previously been treated with tarlatamab.

show original

Select...

I agree not to donate sperm during and for 132 days after my last dose of tarlatamab.

show original

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Side effects data

From 2024 Phase 1 trial • 23 Patients • NCT04885998

57%

Decreased appetite

43%

Fatigue

43%

Dysgeusia

29%

Insomnia

29%

Pyrexia

29%

Weight decreased

29%

Dizziness

14%

Encephalopathy

14%

Gastrooesophageal reflux disease

14%

Upper respiratory tract infection

14%

Weight loss poor

14%

Headache

14%

Restless legs syndrome

14%

Prostatic obstruction

14%

Cough

14%

Anaemia

14%

Sudden death

14%

Cytokine release syndrome

14%

Pneumonia

14%

Neurological decompensation

14%

Neurotoxicity

14%

Confusional state

14%

Atrial fibrillation

14%

Abdominal pain

14%

Constipation

14%

Dysphagia

14%

Gastric disorder

14%

Nausea

14%

Pancreatitis acute

14%

Gait disturbance

14%

Pain

14%

Urinary tract infection

14%

Alanine aminotransferase increased

14%

Aspartate aminotransferase increased

14%

Hypokalaemia

14%

Iron deficiency

14%

Muscle mass

14%

Ataxia

14%

Dysarthria

14%

Leukoencephalopathy

14%

Tremor

14%

Agitation

14%

Urinary tract discomfort

14%

Nasal congestion

14%

Rash maculo-papular

14%

Deep vein thrombosis

100%

80%

60%

40%

20%

Study treatment Arm

Part 1 Cohort 1: Tarlatamab Dose A/Dose B + AMG 404 (SFU1)

Part 1 Cohort 1: Tarlatamab Dose A/Dose B + AMG 404 (EP)

Part 1 Cohort 2: Tarlatamab Dose A/Dose C + AMG 404 (SFU1)

Part 1 Cohort 2: Tarlatamab Dose A/Dose C + AMG 404 (EP)

Part 1 Cohort 3: Tarlatamab Dose A/ Dose D + AMG 404 (SFU1)

Part 1 Cohort 3: Tarlatamab Dose A/ Dose D + AMG 404 (EP)

Part 2 Dose Expansion Cohort: Tarlatamab Dose B + AMG 404 (SFU1)

Part 2 Dose Expansion Cohort: Tarlatamab Dose B + AMG 404 (EP)

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

4Treatment groups

Experimental Treatment

Group I: Part 3: Modified Monitoring SubstudyExperimental Treatment1 Intervention

Participants will receive the selected target dose of Tarlatamab based on findings in Part 1 with reduced Cycle 1 monitoring requirements.

Group II: Part 2: Dose ExpansionExperimental Treatment1 Intervention

Participants will receive the selected target dose of Tarlatamab based on findings in Part 1.

Group III: Part 1: Tarlatamab Low DoseExperimental Treatment1 Intervention

Participants will receive the low dose of Tarlatamab.

Group IV: Part 1: Tarlatamab High DoseExperimental Treatment1 Intervention

Participants will receive the high dose of Tarlatamab.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Tarlatamab

2021

Completed Phase 1

~70

0 / 14Eligibility criteria met

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.

Mechanism Of Action

Side Effect Profile

Prior Approvals

Other Research

The most common treatments for Small Cell Lung Cancer (SCLC) include chemotherapy, immunotherapy, and targeted therapies. Chemotherapy drugs like etoposide and cisplatin work by damaging the DNA of cancer cells, causing them to die. Immunotherapy, such as anti-PD-1 or anti-PD-L1 therapies, boosts the immune system's ability to detect and kill cancer cells. Targeted therapies, like tarlatamab, specifically bind to proteins or antigens on cancer cells, leading to their destruction. These mechanisms are vital for SCLC patients as they help in choosing the most effective treatment, potentially improving survival rates and reducing side effects.